Pfizer says USFDA accepts regulatory submissions for review of tafamidis Medical Dialogues Bureau16 Jan 2019 9:35 AM ISTPfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial...
Bayer, Johnson and Johnson's heart drug Xarelto fails trial to widen use Ruby Khatun Khatun28 Aug 2018 9:45 AM ISTFRANKFURT: Bayer and Johnson and Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sept 2017 9:15 AM ISTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
New AstraZeneca, Amgen drug looks strong rival in severe asthma Ruby Khatun Khatun11 Sept 2017 10:27 AM ISTLONDON: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than...